ImCyse Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $5.16M
Latest Deal Amount
  • Investors
  • 9

ImCyse General Information

Description

Manufacturer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines helps to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, enabling physicians to treat and prevent severe chronic diseases caused by disruptions of the immune system.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
  • GIGA B34
  • Avene de l'Hôpital 1,Sart Tilman
  • 4000 Liege
  • Belgium

ImCyse Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImCyse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 18-Jun-2019 $5.16M 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 18-Jun-2019 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Nov-2017 00.000 00.000 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC 27-Aug-2014 00.000 00.000 000.00 Completed Startup
3. Early Stage VC 01-Nov-2012 00.000 00.000 000.00 Completed Startup
2. Early Stage VC 09-Feb-2011 $270K $270K 00000 Completed Startup
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view ImCyse’s complete valuation and funding history, request access »

ImCyse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 000 000.00 000.00 00 000.00 0.000
Class B 000 000.00 000.00 00 000.00 0.000
Class D 00,000 00.00 00.00 00 00.00 0.000
Class C 0,000 00.00 00.00 00 00.00 0.000
Class E 0,000 000.00 000.00 00 000.00 0.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 469 $24.06 $24.06 1x $24.06 0.05%
Class A 5,861 $24.06 $24.06 1x $24.06 0.61%
To view ImCyse’s complete cap table history, request access »

ImCyse Executive Team (13)

Name Title Board Seat Contact Info
Denis Bedoret Chief Executive Officer
Antoon Oosterhout Ph.D Chief Scientific Officer & Vice President, Research & Development
Luc Elst Ph.D Co-Founder & Director, Research & Development
Vincent Carlier Ph.D Co-Founder & Research & Development Director, Immunology
Jean-marie Saint-Remy Ph.D Co-Founder
You’re viewing 5 of 13 executive team members. Get the full list »

ImCyse Board Members (9)

Name Representing Role Since
Christina Franssen Société Régionale d'Investissement de Wallonie Board Member 000 0000
Hugues Wallemacq Ph.D Noshaq Board Member 000 0000
Jorg Neermann Ph.D Life Sciences Partners Board Member 000 0000
Stefan Yee Self Board Member 000 0000
Stijn Van Rompay Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

ImCyse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImCyse Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Biogenosis Corporation Minority 000 0000 000000 0
Epimède Venture Capital Minority 000 0000 000000 0
Federal Holding and Investment Company Holding Company Minority 000 0000 000000 0
Life Sciences Partners Venture Capital Minority 000 0000 000000 0
Société Régionale d'Investissement de Wallonie Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »